Acebilustat is primarily investigated for its potential therapeutic applications in treating inflammatory conditions. It functions as a leukotriene A4 hydrolase inhibitor, which helps reduce inflammation by blocking the production of pro-inflammatory molecules. This makes it a promising candidate for managing chronic inflammatory diseases such as cystic fibrosis, where excessive inflammation contributes to lung damage. Additionally, it is being studied for its role in alleviating symptoms of other inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease. Its mechanism of action targets the underlying inflammatory pathways, offering a potential treatment option for patients with limited responses to conventional therapies.